Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Year: 2002
Type: article
Source: The Lancet
Authors: Lars H Lindholm, Hans Ibsen, Björn Dahlöf, Richard B Devereux, Gareth Beevers, Ulf de Faire, Frej Fyhrquist, Stevo Julius, Sverre E Kjeldsen, Krister Kristiansson, Ole Lederballe-Pedersen, Markku S Nieminen, Per Omvik, Suzanne Oparil, Hans Wedel, Peter Aurup, Jonathan Edelman, Steven Snapinn
Institutions: University Hospital of Umeå, Umeå University, Glostrup Hospital, Sahlgrenska University Hospital, Birmingham City Hospital, Karolinska University Hospital, Helsinki University Hospital, University of Michigan, Oslo University Hospital, Regionshospitalet Viborg, Haukeland University Hospital, University of Alabama at Birmingham, Nordic School of Public Health, Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1982920623